Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases

Antonio Chiappa, Emilio Bertani, Masatoshi Makuuchi, Andrew P. Zbar, Gianmarco Contino, Giuseppe Viale, Giancarlo Pruneri, Massimo Bellomi, Paolo Della Vigna, Maria Giulia Zampino, Nicola Fazio, Maria Laura Travaini, Giuseppe Trifirò, Carlo Corbellini, Bruno Andreoni

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background/Aims: Hepatic resection in metastatic disease from colorectal cancer offers the best chance in selected cases for long-term survival. Neoadjuvant chemotherapy (NACT) has been advocated in some cases initially deemed irresectable with few reports of the efficacy of such a strategy and the influence of the response to chemotherapy on the outcome of radical hepatic resection. Methodology: Between December 1995 and May 2005, 88 patients with colorectal liver metastases underwent hepatic resection with curative intent. Twenty-five of these patients, (7 males, 18 females, mean age: 58±9 years; range: 40-75 years) deemed as resectable cases at the time of diagnosis were treated with neoadjuvant chemotherapy. A 7-year survival analysis was performed. Chemotherapy included mainly oxaliplatin or irinotecan containing regimens for a median of 6 courses. Results: Fifteen patients (60%) had synchronous and 10 (40%) metachronous metastases. During preoperative chemotherapy tumor regression occurred in 8 cases (32%); stable disease (SD) in a further 10 patients (40%) and progressive disease (PD) developed in 7 cases (28%). The 5-year overall survival for NACT responders was 71% and only 15% for non-responders (p=0.026). Conclusions: The response to chemotherapy is likely to be a significant prognostic factor affecting overall survival after radical hepatic resection for colorectal metastases.

Original languageEnglish
Pages (from-to)829-834
Number of pages6
JournalHepato-Gastroenterology
Volume56
Issue number91-92
Publication statusPublished - May 2009

Fingerprint

Hepatectomy
Liver Neoplasms
Colorectal Neoplasms
Neoplasm Metastasis
Drug Therapy
Liver
irinotecan
oxaliplatin
Survival
Survival Analysis
Neoplasms

Keywords

  • Colorectal liver metastases
  • Disease-free survival
  • Liver resection
  • Neoadjuvant chemotherapy
  • Survival

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases. / Chiappa, Antonio; Bertani, Emilio; Makuuchi, Masatoshi; Zbar, Andrew P.; Contino, Gianmarco; Viale, Giuseppe; Pruneri, Giancarlo; Bellomi, Massimo; Della Vigna, Paolo; Zampino, Maria Giulia; Fazio, Nicola; Travaini, Maria Laura; Trifirò, Giuseppe; Corbellini, Carlo; Andreoni, Bruno.

In: Hepato-Gastroenterology, Vol. 56, No. 91-92, 05.2009, p. 829-834.

Research output: Contribution to journalArticle

@article{53d0752737c54a29a59ffa6862aa0c05,
title = "Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases",
abstract = "Background/Aims: Hepatic resection in metastatic disease from colorectal cancer offers the best chance in selected cases for long-term survival. Neoadjuvant chemotherapy (NACT) has been advocated in some cases initially deemed irresectable with few reports of the efficacy of such a strategy and the influence of the response to chemotherapy on the outcome of radical hepatic resection. Methodology: Between December 1995 and May 2005, 88 patients with colorectal liver metastases underwent hepatic resection with curative intent. Twenty-five of these patients, (7 males, 18 females, mean age: 58±9 years; range: 40-75 years) deemed as resectable cases at the time of diagnosis were treated with neoadjuvant chemotherapy. A 7-year survival analysis was performed. Chemotherapy included mainly oxaliplatin or irinotecan containing regimens for a median of 6 courses. Results: Fifteen patients (60{\%}) had synchronous and 10 (40{\%}) metachronous metastases. During preoperative chemotherapy tumor regression occurred in 8 cases (32{\%}); stable disease (SD) in a further 10 patients (40{\%}) and progressive disease (PD) developed in 7 cases (28{\%}). The 5-year overall survival for NACT responders was 71{\%} and only 15{\%} for non-responders (p=0.026). Conclusions: The response to chemotherapy is likely to be a significant prognostic factor affecting overall survival after radical hepatic resection for colorectal metastases.",
keywords = "Colorectal liver metastases, Disease-free survival, Liver resection, Neoadjuvant chemotherapy, Survival",
author = "Antonio Chiappa and Emilio Bertani and Masatoshi Makuuchi and Zbar, {Andrew P.} and Gianmarco Contino and Giuseppe Viale and Giancarlo Pruneri and Massimo Bellomi and {Della Vigna}, Paolo and Zampino, {Maria Giulia} and Nicola Fazio and Travaini, {Maria Laura} and Giuseppe Trifir{\`o} and Carlo Corbellini and Bruno Andreoni",
year = "2009",
month = "5",
language = "English",
volume = "56",
pages = "829--834",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "91-92",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases

AU - Chiappa, Antonio

AU - Bertani, Emilio

AU - Makuuchi, Masatoshi

AU - Zbar, Andrew P.

AU - Contino, Gianmarco

AU - Viale, Giuseppe

AU - Pruneri, Giancarlo

AU - Bellomi, Massimo

AU - Della Vigna, Paolo

AU - Zampino, Maria Giulia

AU - Fazio, Nicola

AU - Travaini, Maria Laura

AU - Trifirò, Giuseppe

AU - Corbellini, Carlo

AU - Andreoni, Bruno

PY - 2009/5

Y1 - 2009/5

N2 - Background/Aims: Hepatic resection in metastatic disease from colorectal cancer offers the best chance in selected cases for long-term survival. Neoadjuvant chemotherapy (NACT) has been advocated in some cases initially deemed irresectable with few reports of the efficacy of such a strategy and the influence of the response to chemotherapy on the outcome of radical hepatic resection. Methodology: Between December 1995 and May 2005, 88 patients with colorectal liver metastases underwent hepatic resection with curative intent. Twenty-five of these patients, (7 males, 18 females, mean age: 58±9 years; range: 40-75 years) deemed as resectable cases at the time of diagnosis were treated with neoadjuvant chemotherapy. A 7-year survival analysis was performed. Chemotherapy included mainly oxaliplatin or irinotecan containing regimens for a median of 6 courses. Results: Fifteen patients (60%) had synchronous and 10 (40%) metachronous metastases. During preoperative chemotherapy tumor regression occurred in 8 cases (32%); stable disease (SD) in a further 10 patients (40%) and progressive disease (PD) developed in 7 cases (28%). The 5-year overall survival for NACT responders was 71% and only 15% for non-responders (p=0.026). Conclusions: The response to chemotherapy is likely to be a significant prognostic factor affecting overall survival after radical hepatic resection for colorectal metastases.

AB - Background/Aims: Hepatic resection in metastatic disease from colorectal cancer offers the best chance in selected cases for long-term survival. Neoadjuvant chemotherapy (NACT) has been advocated in some cases initially deemed irresectable with few reports of the efficacy of such a strategy and the influence of the response to chemotherapy on the outcome of radical hepatic resection. Methodology: Between December 1995 and May 2005, 88 patients with colorectal liver metastases underwent hepatic resection with curative intent. Twenty-five of these patients, (7 males, 18 females, mean age: 58±9 years; range: 40-75 years) deemed as resectable cases at the time of diagnosis were treated with neoadjuvant chemotherapy. A 7-year survival analysis was performed. Chemotherapy included mainly oxaliplatin or irinotecan containing regimens for a median of 6 courses. Results: Fifteen patients (60%) had synchronous and 10 (40%) metachronous metastases. During preoperative chemotherapy tumor regression occurred in 8 cases (32%); stable disease (SD) in a further 10 patients (40%) and progressive disease (PD) developed in 7 cases (28%). The 5-year overall survival for NACT responders was 71% and only 15% for non-responders (p=0.026). Conclusions: The response to chemotherapy is likely to be a significant prognostic factor affecting overall survival after radical hepatic resection for colorectal metastases.

KW - Colorectal liver metastases

KW - Disease-free survival

KW - Liver resection

KW - Neoadjuvant chemotherapy

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=67651227762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651227762&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 829

EP - 834

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 91-92

ER -